These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 28771009)

  • 1. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models.
    Pathak SM; Schaefer KJ; Jamei M; Turner DB
    J Pharm Sci; 2019 Apr; 108(4):1604-1618. PubMed ID: 30476508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopharmaceutic
    Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
    Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling.
    Ruff A; Fiolka T; Kostewicz ES
    Eur J Pharm Sci; 2017 Mar; 100():42-55. PubMed ID: 28011125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.
    Kowthavarapu VK; Charbe NB; Gupta C; Iakovleva T; Stillhart C; Parrott NJ; Schmidt S; Cristofoletti R
    AAPS J; 2024 Apr; 26(3):44. PubMed ID: 38575716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs.
    Franco YL; Da Silva L; Charbe N; Kinvig H; Kim S; Cristofoletti R
    Pharm Res; 2023 Feb; 40(2):405-418. PubMed ID: 36788156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
    Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
    Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of Precipitation Kinetics From an In Vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs.
    Patel S; Zhu W; Xia B; Sharma N; Hermans A; Ehrick JD; Kesisoglou F; Pennington J
    J Pharm Sci; 2019 Jan; 108(1):574-583. PubMed ID: 30395833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro-In Vivo Correlation in Cocrystal Dissolution: Consideration of Drug Release Profiles Based on Coformer Dissolution and Absorption Behavior.
    Kataoka M; Minami K; Takagi T; Amidon GE; Yamashita S
    Mol Pharm; 2021 Nov; 18(11):4122-4130. PubMed ID: 34618448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
    Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
    Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
    Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
    Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base.
    Berlin M; Ruff A; Kesisoglou F; Xu W; Wang MH; Dressman JB
    Eur J Pharm Biopharm; 2015 Jun; 93():267-80. PubMed ID: 25872159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.